3D Bioprinting Market Report 2026

3D Bioprinting Market Overview

• 3D Bioprinting market size has reached to $2.19 billion in 2025 • Expected to grow to $6.21 billion in 2030 at a compound annual growth rate (CAGR) of 23.2% • Growth Driver: Increasing Incidence Of Chronic Diseases To Fuel The 3D Bioprinting Market • Market Trend: Technological Advancements In 3D Bioprinting With The Bison Bio DLP Printer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under 3D Bioprinting Market?

3D Bioprinting is a type of additive manufacturing that prints live structures layer by layer, mimicking the behavior of actual living systems, using cells and other biocompatible materials like inks, also known as bio-inks. 3D bioprinting materials are mainly used in connection with drug research and most recently as cell scaffolds to help repair damaged ligaments and joints. The main types of components in 3D bioprinting are 3D bioprinters and bio-inks. 3D bioprinters use three-dimensional technology in combination with biocompatible materials to replicate body parts. It is used for bioprinting of tissue, bone, organs, blood vessels tissue, and biomedical parts. The different types of materials include living cells, hydrogels, extracellular matrices, and others. 3D bioprinting is used in research applications, clinical applications, and others and is implemented in several verticals such as research organizations and academic institutes, biopharmaceutical companies, hospitals, and others.

What Is The 3D Bioprinting Market Growth Forecast?

The 3D bioprinting market size is expected to see exponential growth in the next few years. It will grow to $6.21 billion in 2030 at a compound annual growth rate (CAGR) of 23.2%. The growth in the forecast period can be attributed to expansion of personalized medicine, increasing organ transplantation demand, regulatory support for bioprinted tissues, growth in biopharmaceutical research pipelines, advancements in scalable bioprinting platforms. Major trends in the forecast period include tissue engineering for regenerative therapies, patient-specific implant fabrication, advanced bioink formulation development, high-resolution multi-material bioprinting, clinical translation of printed tissues.

Global 3D Bioprinting Market Segmentation

1) By Component: 3D Bioprinters, Bioinks 2) By Material: Living Cells, Hydrogels, Extracellular Matrices, Other Materials 3) By Application: Research Applications, Clinical Application, Other Applications 4) By End User: Research Organization And Academic Institutes, Biopharmaceutical Companies, Hospitals, Other End Users Subsegments: 1) By 3D Bioprinters: Inkjet 3D Bioprinters, Microextrusion 3D Bioprinters, Laser-Assisted 3D Bioprinters, Stereolithography (SLA) Bioprinters 2) By Bioinks: Natural Bioinks, Synthetic Bioinks, Hybrid Bioinks

What Is The Driver Of The 3D Bioprinting Market?

The increasing incidence of chronic diseases is expected to propel the growth of the 3D bioprinting market going forward. A chronic disease is a medical condition that persists over a long period, typically for three months or more, and often continues throughout a person's life. 3D bioprinting is utilized in creating tissue models for chronic disease research and potential organ replacement therapies. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the increasing incidence of chronic diseases is driving the growth of the 3D bioprinting industry.

Key Players In The Global 3D Bioprinting Market

Major companies operating in the 3d bioprinting market are Organovo Holdings Inc., Allevi Inc., Cellink AB, Aspect Biosystems Ltd., Cyfuse Biomedical KK, Poietis SA, TeVido BioDevices, Nano3D Biosciences Inc., RegenHU Ltd., GeSiM mbH, Advanced Solutions Life Sciences LLC, Regenovo Biotechnology Co. Ltd., Regemat 3D S.L., Bio3D Technologies, ROKIT Healthcare Co. Ltd., Inventia Life Science Pvt. Ltd., Vivax Bio LLC, 3D Biotek LLC, 3D Bio Corp, 3D Bioprinting Solutions, BICO Group AB, CollPlant Biotechnologies Ltd., 3D Systems Corporation, EnvisionTEC GmbH, GE HealthCare Technologies Inc., Nuclera Nucleics Ltd.

Global 3D Bioprinting Market Trends and Insights

Major companies operating in the 3D bioprinting market are focusing on developing technologically innovative solutions, such as 3D bioprinters, to enhance the precision and efficiency of tissue engineering and regenerative medicine. 3D bioprinters are devices that use bioinks containing living cells to create three-dimensional tissue and organ structures for medical research and regenerative medicine applications. For instance, in June 2024, Tethon 3D, a US developer of ceramic powder and metal-polymer products, launched the Bison Bio DLP 3D bioprinter, its first foray into the bioprinting market, developed in collaboration with Carima. This innovative printer features adjustable build sizes (30 × 20 mm, 57 × 32 mm, and 96 × 54 mm) and is compatible with Tethon’s proprietary LAP photoinitiator and GelMA hydrogel bioink, essential for bioprinting live tissues. Measuring 24 × 24 × 24 inches and weighing 75 lbs, the Bison Bio is priced at $19,950 and aims to facilitate advancements in healthcare by enabling the creation of complex tissues and organs for biomedical research, ultimately contributing to personalized medicine and regenerative therapies.

What Are Latest Mergers And Acquisitions In The 3D Bioprinting Market?

In February 2025, Eli Lilly and Company, a US-based pharmaceutical company, acquired Organovo’s FXR program (including its lead asset FXR314) for an upfront payment of US $10 million, plus milestone-based payments. Through this acquisition, Lilly aims to advance its pipeline by leveraging Organovo’s 3D-bioprinted human tissue model–derived data to de-risk and develop FXR314 more efficiently. Organovo Holdings, Inc. is a US-based company that provides 3D-bioprinted human tissue models for drug discovery and preclinical testing.

Regional Outlook

North America was the largest region in the 3D bioprinting market in 2025. Asia-Pacific is expected to be the fastest-growing region in the 3D bioprinting market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the 3D Bioprinting Market?

The 3D bioprinting market consists of sales of extrusion-based bioprinting, inkjet-based bioprinting, laser-assisted bioprinting, and stereolithography bioprinting. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.